Iluca150 mg

Iluca 150 mg is a triazole antifungal used to treat and prevent a range of fungal (candidal and cryptococcal) infections. Its indications can be classified by strength of evidence as follows:

Established / FDA-approved uses

• Vaginal candidiasis (vulvovaginal candidiasis)
• Oropharyngeal and esophageal candidiasis
• Systemic Candida infections, including candidemia, disseminated candidiasis, and candida infections of the peritoneum, endocardium, and urinary tract
• Cryptococcal meningitis (including as maintenance therapy to prevent relapse in patients with AIDS)
• Prophylaxis of candidiasis in patients undergoing bone marrow transplantation who are expected to have neutropenia following cytotoxic chemotherapy or radiation therapy

Guideline-supported / commonly used indications

• Dermatophyte infections such as tinea corporis, tinea cruris, tinea pedis, and tinea versicolor (used based on clinical guidelines and long-standing clinical practice, though not all are separately listed in every regulatory label)
• Prevention of recurrent fungal infections in immunocompromised patients (e.g. HIV/AIDS, organ transplant recipients) at increased risk

Off-label uses

• Fungal urinary tract infections and prosthetic device-related candidiasis in select patients, under specialist guidance

Use of Iluca 150 mg should always be guided by a physician's diagnosis and, where possible, fungal culture/susceptibility results.

Each dosage unit of Iluca 150 mg contains Iluca 150 mg as the active pharmaceutical ingredient. It is available in multiple strengths and dosage forms, including capsules/tablets (50 mg, 100 mg, 150 mg, 200 mg), oral suspension (typically 50 mg/5 mL), and intravenous infusion (2 mg/mL, e.g. 100 mg/50 mL or 200 mg/100 mL). Inactive ingredients vary by manufacturer and formulation; refer to the specific product label for excipient details.

Iluca 150 mg is a synthetic, broad-spectrum triazole antifungal agent. It is highly water-soluble and, unlike many older azole antifungals, has excellent oral bioavailability (over 90%), good penetration into cerebrospinal fluid and other body tissues, and a long elimination half-life that generally allows once-daily dosing. Iluca 150 mg is used worldwide for the treatment and prevention of a range of candidal and cryptococcal fungal infections.

Iluca 150 mg belongs to the triazole antifungal class of medicines.

Iluca 150 mg works by inhibiting the fungal cytochrome P450 enzyme 14-alpha-demethylase, which is required for conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. By blocking this enzyme, Iluca 150 mg depletes ergosterol and causes accumulation of methylated sterol precursors, disrupting fungal cell membrane structure and function. This inhibits fungal growth and replication (a fungistatic effect against most Candida species, though it can be fungicidal against some organisms such as Cryptococcus neoformans at achievable concentrations).

Iluca 150 mg is much more selective for fungal cytochrome P450 enzymes than for human cytochrome P450 enzymes compared with older azoles, which contributes to its relatively favorable tolerability profile, although clinically significant human CYP450 interactions still occur (see Drug Interactions).

After oral administration, Iluca 150 mg is rapidly and almost completely absorbed, with peak plasma concentrations reached within 1-2 hours and an elimination half-life of approximately 30 hours, supporting once-daily or once-weekly dosing regimens depending on the indication. It is eliminated primarily unchanged by the kidneys.

Iluca 150 mg capsules/tablets and oral suspension should be swallowed with a glass of water and can be taken with or without food. The oral suspension should be shaken well before use and measured with an accurate dosing device. The intravenous formulation of Iluca 150 mg is for hospital use only and must be administered by slow IV infusion (not exceeding a rate of about 200 mg/hour) by a qualified healthcare professional; it should not be mixed with other infusions unless compatibility has been confirmed.

Iluca 150 mg is a moderate-to-potent inhibitor of the CYP2C9 and CYP3A4 hepatic enzyme systems and can significantly increase plasma concentrations of drugs metabolized by these pathways. Clinically significant, well-verified interactions include:

• Warfarin and other oral anticoagulants: Iluca 150 mg can increase prothrombin time/INR, raising bleeding risk; monitor coagulation parameters closely.
• Sulfonylurea oral hypoglycemics (e.g. glipizide, glyburide, tolbutamide): increased plasma levels can cause significant hypoglycemia; blood glucose should be monitored and dose adjusted if needed.
• Phenytoin: Iluca 150 mg can substantially raise phenytoin levels, risking toxicity; monitor phenytoin concentrations.
• Cyclosporine and tacrolimus: Iluca 150 mg can markedly increase levels of these immunosuppressants, risking nephrotoxicity; dose reduction and level monitoring are recommended.
• Rifampin: reduces plasma concentrations of Iluca 150 mg, potentially reducing efficacy; a dose increase of Iluca 150 mg may be considered.
• QT-prolonging drugs metabolized by CYP3A4 (e.g. cisapride, astemizole, pimozide, quinidine, and terfenadine at higher Iluca 150 mg doses): co-administration is contraindicated because of the risk of serious, potentially fatal cardiac arrhythmias (see Contraindications).
• Midazolam and other benzodiazepines metabolized by CYP3A4: increased sedative effect; dose adjustment may be needed.

Patients should inform their physician of all medications they are taking before starting Iluca 150 mg.

Most patients tolerate Iluca 150 mg well. Reported side effects include:

Common

• Headache
• Nausea, abdominal pain, diarrhea, vomiting
• Dizziness
• Rash
• Altered taste

Less common / serious (seek medical attention)

• Signs of liver injury: yellowing of skin/eyes, dark urine, unusual fatigue, loss of appetite (see Precautions and Warnings)
• Severe skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis (rare)
• Signs of an allergic reaction, including anaphylaxis and angioedema (rare)
• Palpitations or irregular heartbeat, suggestive of QT prolongation (rare)
• Low blood counts (leukopenia, thrombocytopenia) with prolonged use

Patients should seek prompt medical attention if serious symptoms occur while taking Iluca 150 mg.

Pregnancy: A single low dose (150 mg) of Iluca 150 mg used for vaginal candidiasis has not been clearly shown to increase congenital anomaly risk in most studies, but higher doses (400-800 mg/day) or prolonged use during the first trimester have been associated with a pattern of rare, distinct congenital anomalies (including cleft palate, abnormal skull shape, limb bowing, and cardiac defects) in case reports and some observational studies. Iluca 150 mg should be used in pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use in pregnancy or suspected pregnancy, and prolonged/high-dose regimens should generally be avoided unless treating a serious or life-threatening infection.

Lactation: Iluca 150 mg passes into breast milk at concentrations similar to maternal plasma. A single-dose regimen is generally considered compatible with breastfeeding by many references, but a physician should be consulted, particularly for higher or repeated doses, and the infant should be monitored for gastrointestinal effects.

Hepatotoxicity: Rare but serious hepatic reactions, including fatal hepatic failure, have been reported with Iluca 150 mg, primarily but not exclusively in patients with serious underlying medical conditions. Liver function should be monitored in patients receiving prolonged or high-dose therapy, and Iluca 150 mg should be discontinued if signs or symptoms of liver disease develop.

QT prolongation: Iluca 150 mg has been associated with QT interval prolongation and, rarely, torsades de pointes. Use with caution in patients with structural heart disease, electrolyte abnormalities (hypokalemia, hypomagnesemia), or concurrent use of other QT-prolonging drugs, and avoid the specific contraindicated combinations (see Contraindications).

Drug interactions: Iluca 150 mg has significant potential for interaction with other medicines via CYP450 inhibition; review all concurrent medications, including warfarin, sulfonylureas, phenytoin, cyclosporine, and tacrolimus, before and during treatment (see Drug Interactions).

Dermatologic reactions: Rare, serious exfoliative skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred; discontinue Iluca 150 mg if a progressive rash develops.

Adrenal function: Rare cases of adrenal insufficiency have been reported; monitor patients with adrenal dysfunction or those on chronic corticosteroid therapy.

Antimicrobial stewardship: Take Iluca 150 mg exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice.

Symptoms reported with Iluca 150 mg overdose have included hallucinations and paranoid behavior. In case of a suspected overdose of Iluca 150 mg, seek immediate medical attention or contact a poison control center/emergency services. Management is supportive, with general measures (such as gastric lavage if presenting soon after ingestion, and supportive care) as directed by medical professionals; Iluca 150 mg is significantly cleared by hemodialysis (approximately 50% reduction in plasma levels over about 3 hours), which may be considered in severe cases under medical supervision. Do not attempt to manage an overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. The oral suspension, once reconstituted, should be used within the period specified on the label (typically within 2 weeks) and stored as directed. Do not freeze the injectable/IV formulation.

Renal impairment

Iluca 150 mg is primarily eliminated by the kidneys; dose reduction (e.g. giving 50% of the usual dose, or extending the dosing interval) is recommended in patients with reduced creatinine clearance, and patients on regular hemodialysis should receive a full dose after each dialysis session.

Hepatic impairment

Data are limited; use Iluca 150 mg with caution and monitor liver function closely in patients with hepatic impairment.

Elderly

Dose adjustment is generally based on renal function rather than age alone; use standard adult dosing unless renal impairment is present.

Pediatric patients

See Pediatric Uses.

Duration of Iluca 150 mg therapy is indication-specific: a single dose for uncomplicated vaginal candidiasis; at least 2-3 weeks (and at least 2 weeks beyond symptom resolution) for oropharyngeal/esophageal candidiasis; 10-12 weeks after cerebrospinal fluid culture conversion for cryptococcal meningitis, sometimes followed by long-term suppressive therapy; and until neutrophil recovery plus 7 days for bone marrow transplant prophylaxis. The prescribing physician determines exact duration based on clinical and, where available, microbiological response; the full prescribed course of Iluca 150 mg should always be completed unless a physician advises otherwise.

The oral powder for suspension form of Iluca 150 mg should be reconstituted with the volume of water specified on the label (to make, for example, 50 mg/5 mL) and shaken well before each use; refer to the product-specific label for exact reconstitution instructions, as these vary by manufacturer and pack size.

Iluca 150 mg is classified as a triazole antifungal, part of the broader azole antifungal drug class.

Iluca 150 mg selectively inhibits the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, blocking conversion of lanosterol to ergosterol. Depletion of ergosterol, an essential fungal cell membrane component, disrupts membrane integrity and function, inhibiting fungal cell growth and replication.

C (single low-dose regimen for vaginal candidiasis); D (higher-dose or prolonged regimens for other indications) — legacy FDA pregnancy categories.

Iluca 150 mg is approved for use in pediatric patients (including neonates) for treatment of candidiasis and cryptococcal meningitis, dosed on a weight basis (typically 3-12 mg/kg/day depending on indication and severity, not to exceed the maximum adult dose), under close physician supervision. Safety and efficacy for indications and dosing regimens not specifically studied in children have not been established, and pediatric dosing should always be individualized and supervised by a pediatrician. Common adverse effects in children are similar to adults (vomiting, abdominal pain, nausea).